MedX Pitch Deck: 9-Slide Breakdown

MedX is a TSX-V listed company (Stock Symbol: MDX) with a market capitalization of $30 - $35 million as of the deck's publication. The company operates two divisions: therapeutic lasers and SIAscopy skin assessment technology. The core value proposition centers on reducing skin cancer assessment wait times from months to just 72 hours using their DermSecure platform. By transitioning from a pure hardware play to a SaaS model, MedX aims to capture a share of the 420 million people at high risk of melanoma. The deck outlines a tiered pricing strategy (Gold, Platinum, Diamond) and claims to be i…

Key takeaways

• MedX is a publicly traded company on the TSX-V with 131 million shares outstanding and a market cap between $30M and $35M (Slide 2).
• The company operates in 34 countries with regulatory approvals in the USA, Canada, EU, Australia, and Turkey (Slide 2).
• A critical problem identified is the shortage of specialists; Canada has only 565 dermatologists for 37 million people, leading to wait times of 5 to 18 months (Slide 4).
• MedX claims their technology can reduce patient wait times for skin cancer assessments to 72 hours (Slide 4).
• The cost of treating Stage 1 Melanoma is $2,500 with a 97% survival rate, compared to $1,000,000 for Stage 4 with a 15% survival rate (Slide 4).
• The business model is shifting to SaaS, with monthly charges ranging from $200 to $400 per installation (Slide 7).
• The deck lacks a team slide, financial history, or a specific funding 'ask' amount (Slides 1-9).
• Future growth is predicated on 15,000 potential installations, estimated to generate $84 million in top-line revenue (Slide 8).

Frequently asked questions

What is the primary technology MedX uses for skin assessment?

MedX utilizes SIAscopy, a skin assessment technology that captures images 2mm below the skin's surface. According to Slide 5, it is a Class 2 device that provides four pathophysiology views, which the company claims results in higher image quality and lower rejection rates by dermatologists compared to Class 1 competitors.

How does the DermSecure platform work?

DermSecure is a cloud-based telemedicine platform. As shown on Slide 6, a trained technician performs a scan in minutes, which is then uploaded to a HIPAA/PIPEDA compliant network. A contracted dermatologist then reviews the scan in less than two minutes, providing a medical report to the clinic and patient within a 2-day turnaround.

What is the current market valuation of the company according to the deck?

Slide 2 states that MedX is listed on the TSX-V under the symbol MDX. It reports 131 million shares outstanding (201 million fully diluted) with a market capitalization ranging between $30 million and $35 million.

What are the different pricing tiers for the MedX SaaS model?

Slide 7 outlines three tiers: Gold ($200/month, 20 scans), Platinum ($300/month, 30 scans), and Diamond ($400/month, 40 scans). Device costs decrease as the monthly subscription tier increases, ranging from $2,500 for Gold to $1,500 for Diamond.

What are the stated growth targets for the company?

Slide 8 indicates that MedX is in discussions for over 15,000 potential installations. The company estimates that reaching this scale under their SaaS model would represent approximately $84 million in top-line revenue, with a significant portion being recurring.

MedX pitch deck: the facts

Company

MedX

Slides

9

Sector

Healthcare

MedX pitch deck PDF

The full MedX deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the MedX Health Corp. pitch deck was used for

This deck is a 9‑slide investor presentation from 2018 by MedX Health Corp., a Canadian medical device and teledermatology company focused on early skin cancer detection using its SIAscopy imaging technology and associated devices (Siametrics, Simsys, MoleMate). The presentation highlights the clinical and economic burden of melanoma, limited dermatology access in Canada, and positions MedX’s Class II scanning devices plus a browser‑based telemedicine platform as a rapid 72‑hour assessment solution integrating with EMRs. It also describes a strategic pivot toward a SaaS model built around its DermSecure telemedicine platform with global rollout plans, including Canada, the US, the Netherlands and additional regions. The deck was used in the context of MedX’s late‑stage private financing efforts in 2018, alongside a non‑brokered private placement to fund the development and deployment of its DermSecure teledermatology platform.

Business model: Medical device and software company focused on non-invasive skin assessment and teledermatology, monetized via device sales and a recurring SaaS/usage model on its DermSecure telemedicine platform.

Year

2018

Founded

1999

Headquarters

Mississauga, Ontario, Canada.

Industry

Healthcare technology; teledermatology and medical devices for skin cancer assessment.

Round: Non‑brokered private placement by an already public TSX‑V listed company, effectively a follow‑on financing rather than a traditional venture capital round.

Raising: As of November 2018, MedX was initiating a new non‑brokered private placement targeting up to C$2.5 million of units to fund its operations and growth initiatives, including teledermatology expansion.

Raised: MedX completed an additional closing of 1,137,500 units on November 22, 2018, raising approximately C$182,000 as part of a non‑brokered private placement offering originally announced on October 11, 2018, and concurrently announced a new non‑brokered private placement of units to raise up to C$2.5 million from accredited investors.

Use of funds as presented: Public disclosures state that proceeds from subsequent financings were directed toward development and commercial deployment of the SIAscopy on DermSecure telemedicine platform, expansion into occupational health markets, and general corporate purposes; while the 2018 announcement does not itemize uses, it frames the new private placement as funding for MedX’s ongoing growth initiatives.

What happened after the MedX Health Corp. deck

Following the 2018 investor deck, MedX advanced its strategy of building a recurring‑revenue teledermatology business around SIAscopy on DermSecure, expanding into new geographies and occupational health segments while raising additional capital through private placements and convertible notes to support platform rollout and SaaS adoption.

• MedX expanded deployment of its DermSecure teledermatology platform, including rollouts and pilots in markets such as th
• The company continued to develop its SIAscopy on DermSecure platform and teledermatology services, including collaborati
• MedX launched new SaaS products such as SkinSecure, a cloud‑based platform linking SIAscopy devices to contract research
• To fund teledermatology expansion and business model evolution, MedX completed multiple financings, including non‑broker

What the MedX Health Corp. deck got right

• Compelling articulation of the clinical and economic problem. The deck anchors the opportunity in clearly quantified clinical and economic problems, including limited dermatologist availability in Canada (565 dermatologists for 37 million people), long wait times of 5–18 months, and stark contrasts in treatment cost and survival between Stage 1 and Stage 4 melanoma, which strongly supports the need for earlier detection and remote assessment.[slides]
• Differentiated integrated hardware–software teledermatology platform. MedX’s SIAscopy‑based scanners are positioned as Class II devices capable of capturing high‑quality dermoscopic and multispectral images 2 mm below the skin surface, integrated with a patient management system and a secure, browser‑based telemedicine platform, which together create a differentiated, end‑to‑end teledermatology solution compared with Class I imaging competitors.[slides]
• Strong value proposition around 72‑hour remote assessment. The promise of delivering dermatologist assessments within 72 hours via DermSecure addresses a major access gap in dermatology and aligns with later real‑world deployments and pilots showing rapid, non‑invasive imaging and remote assessment workflows.[slides]
• Regulatory and geographical validation supports commercialization story. The deck emphasizes regulatory approvals and a growing target market, consistent with later disclosures that MedX’s devices and SIAscopy on DermSecure platform have regulatory clearances in multiple territories and have been deployed in markets such as the Netherlands and Turkey, lending credibility to its commercialization pathway.
• Ancillary laser therapy business providing diversified revenue. MedX highlights updated laser therapeutic products as a cash‑generating business line alongside teledermatology, suggesting a potential internal funding source for growth and a diversified revenue base, which can be attractive to investors concerned about dependency on a single product line.[slides]
• Early, consistent framing of a recurring SaaS revenue model. The deck’s focus on a SaaS‑based telemedicine model with recurring revenue from a large installed base anticipates MedX’s later financing and product announcements, which consistently highlight the pivot from device‑only revenues to subscription and usage‑based income on DermSecure.

What could have been stronger

• Aggressive revenue projections without supporting traction or assumptions. The deck references an $84 million top‑line revenue opportunity based on 15,000 potential installations under a SaaS model, but does not show any underlying sensitivity analysis, traction metrics, or unit economics (e.g., installation conversion rates, churn, or per‑site ARPU) that would substantiate how realistic this pipeline is.[slides]
• Limited evidence presented for technology differentiation claims. While the presentation claims MedX’s scanner is the only Class II device capturing dermoscopic and multiple pathophysiology views 2 mm below the skin, and that competitors are only Class I devices with poor image quality, it does not provide comparative clinical data, head‑to‑head studies, or regulatory references in the deck itself to validate these assertions.[slides]
• Overly broad short‑term geographic and channel focus. The strategy slide lists multiple geographies (Canada, US, Netherlands, Mexico, Spain, Latin America, France, Germany) and several channels (medical clinics, pharmacies, airlines, military, occupational health, unions) in a single near‑term plan, but does not describe a phased rollout, prioritization, or resource allocation, making it difficult to assess execution focus or sequencing.[slides]
• Lack of historical financial and customer traction detail. Although the summary references regulatory approvals and sales in multiple countries and notes updated laser therapeutic products generating cash flow, the deck does not provide quantitative figures for historical revenue, gross margins, or customer counts, limiting an investor’s ability to assess commercial traction and financial health.[slides]
• Insufficient detail on integration, AI readiness, and compliance. The deck highlights integration with EMR platforms and an AI‑capable browser‑based telemedicine system but does not specify the maturity of these integrations, existing reference customers, or any regulatory and data‑security certifications beyond the Class II device status, leaving implementation and compliance risk under‑addressed.[slides]

How an investor would read this deck

What draws attention

• Verify that the SIAscopy devices and DermSecure platform are indeed cleared or approved by regulators (Health Canada, FDA, TGA, CE) for the indicated uses and that the Class II status claimed in the deck aligns with current device registrations.
• Scrutinize the 15,000 potential installations and $84 million revenue figure by examining the underlying pipeline, including signed agreements, pilots, conversion rates, and typical contract values in each target geography.[slides]
• Evaluate the scalability of the proposed SaaS model, including infrastructure, support and training requirements for distributed clinic and pharmacy networks, and the company’s ability to support multiple international markets concurrently.
• Assess MedX’s dual focus on teledermatology and laser phototherapy products to determine whether the latter genuinely provides sustainable cash flow to fund growth or distracts from the core SaaS telemedicine business.
• Consider competitive dynamics in teledermatology and dermoscopy imaging, validating claims that competitors are only Class I devices with inferior image quality and assessing how quickly rivals may close any technical gap.[slides]

Risks that stand out

• Execution risk in simultaneously targeting multiple geographies and customer types (clinics, pharmacies, occupational health) with a relatively small organization, potentially stretching sales and implementation resources thin.
• Regulatory and compliance risk, including maintaining approvals across multiple jurisdictions and ensuring the telemedicine platform continues to meet evolving data privacy and security requirements.
• Competitive risk from other teledermatology platforms and dermoscopy imaging solutions that may offer integrated workflows or AI‑assisted diagnostics, potentially eroding MedX’s differentiation based on SIAscopy and Class II device status.
• Adoption risk in primary care and pharmacy settings, where workflow changes, training requirements, and reimbursement structures may slow uptake of teledermatology screening solutions despite clinical need.
• Financing risk, as MedX has relied on repeated private placements and later convertible note financings to fund platform rollout and may need continued access to capital markets to sustain growth and international expansion.

Questions this deck invites

• What is the current installed base of SIAscopy devices and DermSecure sites, and how many of the 15,000 potential installations mentioned in the deck have converted into paying customers or pilots since 2018?
• What are the regulatory clearances and indications for each hardware product (Siametrics, Simsys, MoleMate) and the DermSecure platform in each target territory, and are there any outstanding regulatory risks or limitations on commercializa
• How does MedX price its SaaS offering (per report, per site subscription, or hybrid), what are current ARPU and gross margins, and how do these differ between markets like Canada, the Netherlands, and emerging geographies?
• What clinical validation and health‑economic data exist demonstrating that MedX’s technology reduces time to diagnosis, improves outcomes, and generates cost savings compared with standard care, and how are these data being used in payer an
• How is MedX prioritizing countries and channels (e.g., pharmacies vs. clinics vs. occupational health) in its rollout plan, and what partnerships or distribution agreements (such as those in the Netherlands, Turkey, and the UK) are in place

What founders can take from the MedX Health Corp. deck

• A clear articulation of the clinical problem, such as long dermatologist wait times and differences in survival and treatment costs between early and late‑stage melanoma, can strongly frame the value proposition for a telemedicine‑based diagnostic pathway.[slides]
• Positioning a hardware device as part of a broader SaaS and telemedicine ecosystem, rather than as a stand‑alone product, allows a company to pivot toward recurring revenue and align with investor interest in scalable software platforms.
• Quantifying a potential installation base and associated top‑line revenue, even if aspirational, can help investors size the opportunity, but it must be paired with credible assumptions and evidence of pipeline quality to be persuasive.[slides]
• Highlighting regulatory approvals across multiple territories and existing sales can help de‑risk a medtech investment story, especially when combined with a telemedicine platform that has already been deployed in real‑world pilots or country rollouts.
• Maintaining a secondary, cash‑generating product line (e.g., laser therapeutic devices) can be positioned as a way to support growth of the core SaaS platform, though companies must demonstrate that this does not dilute focus on the primary strategic initiative.
• Demonstrating integration with EMR systems and collaboration with digital health partners can strengthen a telehealth pitch by showing how the platform fits into broader healthcare IT ecosystems and standards.

MedX Health Corp. pitch deck: common questions

What does MedX (MedX Health Corp.) do?

MedX Health Corp. is a Mississauga, Ontario–based medical device and software company focused on non‑invasive skin assessment and teledermatology, using its proprietary SIAscopy technology embedded in devices such as Siametrics, Simsys and MoleMate, and delivered through its DermSecure telemedicine platform for early detection and assessment of suspicious skin lesions.

What business model does MedX’s 2018 investor deck propose?

The 2018 investor deck describes a shift from a primarily device‑sales business to a SaaS‑driven teledermatology model built around DermSecure, where MedX earns recurring revenue based on the number of patient reports generated and subscriptions to its cloud‑based telemedicine and patient‑management platform.

How is MedX trying to reduce skin cancer diagnosis wait times?

The deck emphasizes that MedX’s Class II SIAscopy‑based scanners can image 2 mm below the skin’s surface and, combined with DermSecure, provide dermatologists with high‑quality dermoscopic and multispectral images plus patient data, enabling remote assessment of suspicious lesions within approximately 72 hours, compared with Canadian wait times of 5–18 months for in‑person dermatologist visits.[slides]

Which markets and channels does MedX target in this deck and afterwards?

The 2018 deck highlights expansion into Canada, the United States, the Netherlands and other European and Latin American markets via DermSecure, targeting medical clinics, pharmacy chains and at‑risk occupational groups; subsequent disclosures and news releases describe deployments and pilots in markets such as the Netherlands, Turkey and the UK through channel and distribution partners.

What fundraising activity is associated with MedX around the time of this deck?

Public disclosures state that MedX has raised capital through non‑brokered private placements and, later, convertible note financings to fund development and rollout of its SIAscopy on DermSecure telemedicine platform and expansion into occupational health; in November 2018 MedX closed an additional C$182,000 as part of a previously announced private placement and simultaneously launched a new private placement targeting up to C$2.5 million of units.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

• DermSecure Teledermatology Platform | MedX Health
• MedX Health: Skin Cancer Screening Technology
• MedX Health Corp. Announces the Rollout of DermSecure® in the...
• MedX Health Launches SkinSecure™ to Bring Direct, Non...
• MedX Health and Health Partners Sign Commercial Agreement Following Successful UK Pilot
• Collaboration Between Smile CDR, MedX and Blanc Labs to Advance Global Evolution of Teledermatology
• MedX Extends Private Placement: Fueling Telemedicine Growth in Skin Health
• Teledermatology - MedX Health

MedX pitch deck slides

What each slide of the MedX pitch deck says

Slide 1

k4 0 [&) ® Investor Deck TN |||) = Therapeutic Laser & Skin Assessment System 2) SIMSYS" MoleMate

Slide 2

MedX — Short Overview J TSX-V listed company Stock Symbol MDX = 131 million shares o/s (201 million fully diluted) Market Cap - $30 - $35 million J 2 Major Product Divisions = Therapeutic Lasers and LED devices (Steady Growth/ Cash Flow) = SlAscopy -skin assessment technology (Global Market Opportunity/SaaS Model) OJ Laser Division now focused on National Distributors / Huge Opportunity in Dental Laser Market J SlAscopy - proven performance: = Operating in over 200 pharmacies in 4 countries = Regulatory approvals in USA, Canada, EU — 34 countries, Australia, Turkey and shortly Mexico = ~19 Peer Reviewed Research Papers Class 2 Device = Recent Release of DermSecure Platform makes MedX infini…

Slide 3

Skin Cancer is one of the fast growing cancers SKIN CANCERS More than 420 million people at high risk of Melanoma World Health Organization — 2016 .':. SIAMETIQCS" SIMSYS™ Mole

Slide 4

Problems impacting successful outcome of skin cancer + Canada has only 565 Dermatologists serving 37 million people. + Wait times to see a Dermatologist in Canada can be between 5 to 18 months under the current referral method. * Quebec represents 23% of the Canadian population almost 40% of Skin Cancer Deaths because of overexposure to sun and long wait times. » Early detection increases chances of survival...a Stage 1 Melanoma cost $2,500 to treat and the 10 year survival rate is 97%. A Stage 4 Melanoma cost $1,000,000 to treat and the 10 year survival rate is 15%. * MedX's Technology reduces wait times down to 72 hours using its advanced imaging scanner (2mm below skin's surface) and its…

Slide 5

MedX's offers a complete rapid assessment solution UMedX offers patients a 72 hour turnaround on their skin cancer assessment U MedX's scanner is the only Class 2 device that captures a Dermascopic image as well as 4 Pathophysiology views 2 mm below the skins surface. Perfect image capture everytime. UMedX''s has a Patient Management System designed by Dermatologists to capture all relevant information to aid a Dermatologist with a rapid assessment UMedX's patient Management System integrates with current EMR platforms UMedX's has a secure browser based, device agnostic telemedicine platform that has Al capability UMedX''s Competitors are only Class 1 devices with poor image quality. Compet…

Slide 6

Telemedicine Software Platform(DermSecure): Many Points of Service + Remote Dermatologist Assessment Scan performed by DermSecure Network Dermatologists process takes minutes Hub & Spoke Model 0 gq |= | — i A { od Medical Report: Dermatologist: V4 * To clinic, patient, family + SlAscan assessment physician (<2 min/scan) Giitooiias: + 2 day turnaround } ) * Mole t ici @- . oo image stored for future SRS a comparison ft Strat = °— : * Mole suspicious; appointment Rly 3 at dermatologist expedited - 10%, sIAMETRICS SIMSYS™ Moleliaie

Slide 8

Short Term Growth Strategy — Key elements U Launch of fully integrated Telemedicine platform (DermSecure) = Leveraging Dermatologists over multiple locations: Canada, Netherlands, US working with VA, DND, Hospital groups = Add Med Clinic and Pharmacy chains in Canada, USA = Deliver solutions for at-risk groups — airlines, military, occupational health, farm workers, police, union O Launch Telemedicine platform with channel partners in Mexico, Spain, Latin America, France, Germany 0 MedX is currently in discussions with over 15,000 potential installations. Based on MedX SaaS Model that would represent $84 million top line revenue and a large percentage of that would be recurring revenue O Me…

Slide 9

Summary v" Proven technology: regulatory approval, and sales in multiple countries in a growing target market v" New Telemedine Platform will be a game-changer in how MedX will be able to access markets worldwide v" Recurring revenue from growing and potentially large, global installed base v' Laser therapeutic products have been updated — growing business that generates cash flow to support growth

Slide text above is read directly from the MedX deck PDF embedded on this page.

Related fundraising guides (24)

• Condense Pitch Deck Teardown: Solving the 'Pre-Recorded' Problem in Metaverse Live Events
• Odeko Pitch Deck Teardown: A Masterclass in Obfuscating Real Traction Numbers
• Covey Pitch Deck Teardown: Decentralizing Asset Management via Immutable Track Records
• Yalo Pitch Deck Teardown: Dominating Enterprise Conversational AI via WhatsApp
• Dalan Animal Health Pitch Deck Teardown: A $3.5M Seed for the First Honeybee Vaccine
• Swipes Pitch Deck Teardown: A Minimalist Approach to Productivity Fundraising
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods
• Moonlight Pitch Deck Teardown: A Community-First Approach to Remote Engineering
• Depict.ai Pitch Deck Teardown: A Masterclass in Traction-First Seed Fundraising
• Connected Analytics Pitch Deck Teardown: Solving the Cash-Loyalty Gap in Africa
• ElasticStage Pitch Deck Teardown: Solving the 12-Month Vinyl Supply Chain Bottleneck
• Orchid Pitch Deck Teardown: A Masterclass in High-Stakes Clinical Validation
• Eliyan Pitch Deck Teardown: Solving the Chiplet Interconnect Bottleneck for AI
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• EnergyX Pitch Deck Teardown: A Masterclass in Industrial Validation and Scientific Pedigree
• 10KC Pitch Deck Teardown: A $56M Growth Round Built on Enterprise Social Proof
• Equinom Pitch Deck Teardown: Solving the 250% Plant-Based Cost Gap Through Seed Genetics
• Aceiss Pitch Deck Teardown: A Masterclass in Team Credibility and Problem Framing
• Factorial Pitch Deck Teardown: A Narrative-Driven Series C Strategy for HR Tech
• Agave Games Pitch Deck Teardown: A $7M Seed Round Built on Mobile Gaming Pedigree
• Examedi Pitch Deck Teardown: A Lean Vision for Latin American Healthcare Logistics
• AgomAb Therapeutics Pitch Deck Teardown: A Masterclass in Biotech Pipeline Visualization
• Fintor Pitch Deck Teardown: A $6.2M Seed Round Built on Fractional Real Estate Liquidity
• airSlate Pitch Deck Teardown: A $51.5M Series C Masterclass in Growth and Product Consolidation

Browse companies alphabetically (1)

• Pitch decks from companies starting with M

More pitch deck teardowns (16)

• Maybe Pitch Deck Breakdown: Modernizing Financial Planning & Wealth Management
• Maza Pitch Deck Teardown: Solving Financial Identity for the Non-SSN Market
• MBE Academy Pitch Deck Teardown: Scaling Vocational Training in Nigeria
• Miami City Center Pitch Deck Teardown: A $90.8M Real Estate Play for EB-5 Immigrant Investors
• MCIG Pitch Deck Teardown: A Multi-Vertical Conglomerate Approach to Cannabis Ancillaries
• McLovin Pitch Deck Teardown: Disrupting Pet Nutrition Through Supply Chain Efficiency
• mcSquares Pitch Deck Breakdown: A Masterclass in Unit Economics and Traction for D2C
• MDNA Pitch Deck Teardown: Leveraging Mitochondrial DNA for Early Cancer Detection
• MechanicBaba Pitch Deck Teardown: A Post-Pilot Look at India's Car Service Market
• MeCloud Pitch Deck Breakdown: 44 Million Monthly Views And No Ask
• Medable Pitch Deck Breakdown: Scaling Decentralized Clinical Trials with a $304M Series D
• Medalist Diversified Pitch Deck Teardown: A Regional REIT Focus on Secondary Markets
• Medalist Diversified REIT Pitch Deck Teardown: A Regional Real Estate Consolidation Play
• Medal.tv Pitch Deck Teardown: A Product-First Narrative for a $45M Series C
• MedArrive Pitch Deck Breakdown: Leveraging EMS Networks for In-Home Care Delivery
• MedCrypt Pitch Deck Breakdown: Leveraging Regulatory Tailwinds in Medical Device Cybersecurity

Recently published pitch deck teardowns (12)

• Miga Health Pitch Deck Teardown: A $12M Seed Narrative Built on Macro Health Trends
• Beatstoc Pitch Deck Breakdown: A $421M Projection With No Traction Behind It
• OroraTech Pitch Deck Teardown: A Masterclass in Product-Led Geospatial Storytelling
• Ovom Pitch Deck Teardown: A Full-Stack Hybrid Approach to AI Fertility Care
• Paleo Pitch Deck Teardown: A 10-Slide Masterclass in Scientific Differentiation
• Papercup Pitch Deck Teardown: How AI-Powered Dubbing Raised a $20M Series A
• Parafin Pitch Deck Teardown: A Masterclass in Embedded Credit Infrastructure Strategy
• Pave Pitch Deck Teardown: A Masterclass in Data Flywheels and Explosive SaaS Growth
• Patient21 Pitch Deck Teardown: Scaling a Digi-Physical Healthcare Ecosystem in Europe
• Patchwork Health Pitch Deck Teardown: A Category-Creation Play for Healthcare Workforce SaaS
• Pebble Pitch Deck Teardown: A $6.2M Seed Round Built on Anti-Banking Sentiment
• PilotDesk Pitch Deck Teardown: A Lean $3M Seed Deck Focused on Ad-Ops Automation

Fundraising library · Pitch deck examples · Investor directory · Founder database